{"type":"trials","record":{"id":41616,"source_id":"clinicaltrials-gov","external_id":"NCT06550011","title":"Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Intravitreal (IVT) Injection of ABI-110 (AAV2.N54-VEGF Trap) in Subjects With Neovascular (Wet) Age-Related Macular Degeneration (wAMD), Including Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV)","brief_summary":"This will be a clinical study to assess initial safety and tolerability of IVT ABI-110 in patients diagnosed with wet macular degeneration (wAMD), including symptomatic macular PCV.","overall_status":"Active Not Recruiting","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Avirmax Biopharma Inc","enrollment":18,"countries":["United States"],"start_date":"2024-08-07","completion_date":"2031-01-16","last_update_date":"2026-02-12","source_url":"https://clinicaltrials.gov/study/NCT06550011","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 89 Years","comparator":null,"organization":"Avirmax Biopharma Inc","interventions":["ABI-110 Low Dose","ABI-110 Medium Dose","ABI-110 High Dose"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Safety and Tolerability — 52 weeks","Preliminary Efficacy — 52 weeks","Pharmacokinetics and Pharmacodynamics — 52 weeks","Immunogenicity — 52 weeks","Optimal Dose — 52 weeks"],"design_description":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Neovascular (Wet) AMD","ABI-110 Low Dose","ABI-110 Medium Dose","ABI-110 High Dose"],"relevance_confidence":80,"source_quality_score":100,"freshness_score":85,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06550011","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2024-08-07 to 2031-01-16","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years to 89 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.842Z","intervention":["ABI-110 Low Dose","ABI-110 Medium Dose","ABI-110 High Dose"],"participants":18,"study_design":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Safety and Tolerability — 52 weeks","Preliminary Efficacy — 52 weeks","Pharmacokinetics and Pharmacodynamics — 52 weeks","Immunogenicity — 52 weeks","Optimal Dose — 52 weeks"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41616","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}